Condition: Advanced Malignant Solid Tumor · Malignant Pleural Effusion · Pleura Carcinoma · Sponsor: Suzhou Maximum Bio-tech Co., Ltd.
This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy.. Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.
This description comes directly from the study's public registry record.
shuhang wang, Doctoral · 010-87788713 · snowflake201@gmail.com
ning jiang, Doctoral · 010-87788165 · jiangn12@foxmail.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06726564